Transvercid 14.54mg/12mm 8 devices for cutaneous application

The use of verrucides must be subject to great caution in the event of arteritis, diabetes and in subjects suffering from neuropathies. In the event of failure after one month of treatment or in the event of a recurrence, the action to be taken must be reassessed. In the event of pain, irritation, ulceration, bleeding, treatment should be discontinued. Apply the device to the wart to be treated, avoiding contact with healthy skin and/or mucous membranes.